-
公开(公告)号：KR100385364B1
公开(公告)日：2003-05-27
申请号：KR1020020052421
申请日：2002-09-02
IPC: C07D265/22
Abstract: PURPOSE: Provided are azetidinone compound of the formula(I) as an intermediate useful for the manufacture of carbapenem antibiotics and a process for the preparation thereof. CONSTITUTION: The azetidine compound is represented by the formula(I). It is useful as an intermediate for the manufacture of beta-methylcarbapenem antibiotics and manufactured by reacting 4-acetoxy-azetidine compound of the formula(II) and alpha-halo propionic acid amide compound of the formula(III).
Abstract translation: 目的：提供式（I）的氮杂环丁酮化合物作为可用于制备碳青霉烯类抗生素的中间体及其制备方法。 构成：氮杂环丁烷化合物由式（I）表示。 它可用作制备β-甲基碳青霉烯类抗生素的中间体，并通过使式（II）的4-乙酰氧基 - 氮杂环丁烷化合物与式（III）的α-卤代丙酰胺化合物反应制备。
-
公开(公告)号：KR1020020042218A
公开(公告)日：2002-06-05
申请号：KR1020000072016
申请日：2000-11-30
Applicant: 한국화학연구원
CPC classification number: A61K9/1075 , A61K9/4808 , A61K31/366
Abstract: PURPOSE: A pharmaceutical compositions for hypercholesterolemia treatment using of self microemulsifying drug delivery system is provided, thereby improving the solubility and bioavailability of a drug hardly dissolved. CONSTITUTION: The pharmaceutical composition useful for hyperlipidemia treatment using a self microemulsifying drug delivery system(SMEDDS) comprises 1 to 20 wt.% of statin, 5 to 60 wt.% of surfactant, 10 to 60 wt.% of solubilizing agent and 10 to 60 wt.% of co-surfactant, wherein the statin is lovastatin or simvastatin; the surfactant is selected from caster oils, substituted caster oils, twins, spans and bridge; the solubilizing agent is selected from fatty acid ester consisting of propyleneglycol monocaprylate, polyglycolide of oleic acid and linoleic acid, propyleneglycol monolaurate and polyglyceryl dioleate, vegetable oils consisting of coconut oil, olive oil, corn oil, caster oil, macadamia nut oil, apricot oil and unsaturated fatty acid, purified oil, and hydrophobic solubilizing agent; and the co-surfactant is selected from polyethyleneglycol, propylene glycol, dimethylisosorbid and diethyleneglycolmonoethylether.
Abstract translation: 目的：提供使用自微乳化药物递送系统的高胆固醇血症治疗药物组合物，从而提高难溶性药物的溶解度和生物利用度。 构成：使用自微乳化药物递送系统（SMEDDS）用于高脂血症治疗的药物组合物包含1至20重量％的他汀类，5至60重量％的表面活性剂，10至60重量％的增溶剂和10至 60重量％的辅助表面活性剂，其中他汀类是洛伐他汀或辛伐他汀; 表面活性剂选自脚轮油，取代脚轮油，双胞胎，跨度和桥梁; 增溶剂选自由丙二醇单辛酸酯，油酸聚亚油酸和亚油酸组成的脂肪酸酯，单月桂酸丙二醇酯和聚甘油二油酸酯，由椰子油，橄榄油，玉米油，脚轮油，澳洲坚果油，杏仁油组成的植物油 和不饱和脂肪酸，纯化油和疏水增溶剂; 共表面活性剂选自聚乙二醇，丙二醇，二甲基异山梨醇酯和二乙二醇单乙醚。
-
公开(公告)号：KR100481618B1
公开(公告)日：2005-04-08
申请号：KR1020020022024
申请日：2002-04-22
Applicant: 한국화학연구원
Abstract: 본 발명은 하기 화학식 1로 표시되는 이트륨 가돌리늄계 적색 형광체의 제조방법에 관한 것으로서, 본 발명의 방법에 따라, 분무 용액 제조시 구연산과 같은 유기산 및 에틸렌글리콜과 같은 다가 알코올 용액을 적정비율로 첨가하고, 또한 탄산나트륨과 같은 융제를 첨가하여 제조된 이트륨 가돌리늄계 적색 형광체는, 속이 찬 나노 크기의 입자이므로, 발광특성이 우수하고 입도 분포가 향상되어 평판 디스플레이 및 삼파장 램프용 발광층에 유용하게 사용될 수 있다:
(Y
1-x Gd
x )
2 O
3 :Eu
y
상기 식에서, 0≤x≤1이고, 0.001≤y≤0.5 이다.-
公开(公告)号：KR1020020070544A
公开(公告)日：2002-09-10
申请号：KR1020010010385
申请日：2001-02-28
Applicant: 주식회사 아모레퍼시픽그룹 , 한국화학연구원 , 선진뷰티사이언스(주)
CPC classification number: A61K8/29 , A61K8/25 , A61K2800/621 , A61Q1/02 , A61Q17/04
Abstract: PURPOSE: A process of preparing double silica-titania composite powders by allowing silica to support titanium dioxide and then coating the surface of the silica with titanium oxide is provided. Whereby, the composite powders are excellent in irregular reflection and low in hiding power and can be used in a make-up product, ultraviolet screening products, etc.. CONSTITUTION: Silica is allowed to support a large amount of titanium dioxide by the reaction of silica, titanium alkoxide and an aqueous alcohol solution to produce a silica-titania composite carried with titanium dioxide, which is reacted with titanium chloride and the aqueous alcohol solution to produce silica-titania composite powder, which are surface-modified with silicon oil or a fatty acid soap to produce the double silica-titania composite powder.
Abstract translation: 目的：提供二氧化硅 - 二氧化钛复合粉末的制备方法，该方法是通过使二氧化硅支持二氧化钛，然后用二氧化钛涂覆二氧化硅表面。 因此，复合粉末的不规则反射性优异，遮盖力低，可用于化妆品，紫外线防护产品等。构成：通过二氧化硅的反应，可以使二氧化硅支持大量的二氧化钛 二氧化硅，钛醇盐和醇水溶液，以制备二氧化钛载体的二氧化硅 - 二氧化钛复合物，其与氯化钛和醇水溶液反应，以生产二氧化硅 - 二氧化钛复合粉末，其用硅油或 脂肪酸皂生产双重二氧化硅 - 二氧化钛复合粉末。
-
公开(公告)号：KR1020020006889A
公开(公告)日：2002-01-26
申请号：KR1020000040396
申请日：2000-07-14
Applicant: 한국화학연구원
IPC: C07D205/08
Abstract: PURPOSE: Provided are 2-arylethenyl carbapenem derivative of the formula(1) and its pharmaceutically acceptable salt which have therapeutic effect in methicillin resistant staphylococcus aureus(MRSA) infection. And its manufacturing method and an antibacterial composition containing it as an active ingredient are also provided. CONSTITUTION: 2-arylethenyl carbapenem derivative is represented by the formula(1), wherein R is halogen, nitro, hydroxy or cyano substituted phenyl or fused aryl group; or halogen or C1-3 alkyl group substituted monocyclic, bicyclic or tricyclic 5 or 6 membered hetero aryl group containing at least one of O, S or N atom; and M is hydrogen or zwitterion forming pharmaceutically acceptable salts.
Abstract translation: 目的：提供式（1）的2-亚乙烯基碳青霉烯衍生物及其药用盐，其在耐甲氧西林金黄色葡萄球菌（MRSA）感染中具有治疗作用。 还提供其制造方法和含有它作为活性成分的抗菌组合物。 构成：2-亚乙烯基碳代青霉烯衍生物由式（1）表示，其中R是卤素，硝基，羟基或氰基取代的苯基或稠合芳基; 或含有O，S或N原子中的至少一个的卤素或C 1-3烷基取代的单环，双环或三环5或6元杂芳基; M是氢或两性离子形成药学上可接受的盐。
-
Patent Agency Ranking
公开(公告)号：KR100231498B1
公开(公告)日：1999-11-15
申请号：KR1019970060989
申请日：1997-11-19
Applicant: 한국화학연구원
IPC: C07D471/04
Abstract: 본 발명은 그람 양성균은 물론 녹농균을 제외한 그람 음성균에 대하여 우수한 항균 작용을 나타내는, 하기 화학식 1a 또는 화학식 1b로 표시되는 카르바페넴 유도체 화합물, 이의 제조 방법 및 이를 포함하는 약제학적 조성물을 제공한다.
식 중, R은 수소, 카르복실 음이온, 카르복실 보호기, 또는 제약학상 허용가능한 무기 또는 유기염이고, R
1 은 수소 또는 히드록시 보호기이며, R
2 는 C
1 내지 C
5 의 시클릭 또는 비시클릭 저급 알킬기 또는 방향족 알킬기이거나, 또는 질소, 황 및 산소로 이루어지는 군으로부터 선택된 1개 이상의 헤테로 원자를 함유하는 모노 또는 비시클릭, 포화 또는 불포화 고리인, 임의 치환된 헤테로시클릭 라디칼이고, R
3 은 수소, C
1 내지 C
5 의 시클릭 또는 비시클릭 저급 알킬기, 카르바모일기 또는 아세틸기이다.-
公开(公告)号：KR100411195B1
公开(公告)日：2003-12-18
申请号：KR1020000056496
申请日：2000-09-26
Applicant: 한국화학연구원
IPC: A61K9/24
Abstract: PURPOSE: Provided is a controlled release pellet containing ketorolac tromethamine, thereby reducing dosage and consequently increasing drug stability and decreasing side effects. CONSTITUTION: The controlled release pellet containing ketorolac tromethamine characteristically consists of a crystalline core(1) having a size of 300-1000 micrometer, an inner layer(2) including ketorolac tromethamine, and a controlled release type of outer layer(3) containing Eudragit as an essential ingredient and optionally a water-soluble polymer.
Abstract translation: 目的：提供含有酮咯酸氨丁三醇的控释小丸，由此减少剂量并因此增加药物稳定性并减少副作用。 构成：含有酮咯酸氨丁三醇的控释小丸特征性地由尺寸为300-1000微米的晶体核（1），包含酮咯酸氨丁三醇的内层（2）和含Eudragit的控释型外层（3）组成 作为必要成分和任选的水溶性聚合物。
-
公开(公告)号：KR1020030090983A
公开(公告)日：2003-12-01
申请号：KR1020020028890
申请日：2002-05-24
Applicant: 한국화학연구원
IPC: C09K11/78
CPC classification number: C09K11/7787 , C01P2004/03 , C01P2004/60 , C01P2004/61 , C01P2004/62 , C04B35/6267 , C04B2235/3224 , Y02B20/181
Abstract: PURPOSE: A red fluorescent substance for VUV(Vacuum UltraViolet), its preparation method and a plasma display panel or light emitting lamp containing the fluorescent substance are provided, to obtain a fluorescent substance having a high absorption peak at a range of VUV and an excellent emission luminance. CONSTITUTION: The red fluorescent substance is represented by (Y1-a-b-cGdaEubMc)2O3, wherein M is a rare earth metal selected from the group consisting of Dy, Sm, Nd, Tm, Pr and Sc; and 0
Abstract translation: 目的：提供用于VUV（真空紫外线）的红色荧光物质及其制备方法和含有该荧光物质的等离子体显示面板或发光灯，以获得在VUV范围内具有高吸收峰的荧光物质和优异的荧光物质 发光亮度。 构成：红色荧光物质由（Y1-a-b-cGdaEubMc）2O3表示，其中M是选自Dy，Sm，Nd，Tm，Pr和Sc的稀土金属; 0 <= a <1，0.005 <= b <= 0.2，0.00001 <= c <0.1。 该方法包括以下步骤：在溶剂中将钇化合物，钆化合物，选自Dy，Sm，Nd，Tm，Pr和Sc的稀土金属的金属化合物，柠檬酸和乙二醇溶解到 制备前体溶液; 在300-1,500℃干燥和加热前体溶液，通过气溶胶发生剂喷雾溶液以制备荧光物质粉末; 并将荧光物质粉末在800-1,500℃加热1-5小时。
-
公开(公告)号：KR1020020079654A
公开(公告)日：2002-10-19
申请号：KR1020020052421
申请日：2002-09-02
IPC: C07D265/22
Abstract: PURPOSE: Provided are azetidinone compound of the formula(I) as an intermediate useful for the manufacture of carbapenem antibiotics and a process for the preparation thereof. CONSTITUTION: The azetidine compound is represented by the formula(I). It is useful as an intermediate for the manufacture of beta-methylcarbapenem antibiotics and manufactured by reacting 4-acetoxy-azetidine compound of the formula(II) and alpha-halo propionic acid amide compound of the formula(III).
Abstract translation: 目的：提供式（I）的氮杂环丁酮化合物作为制备碳青霉烯类抗生素的中间体及其制备方法。 构成：氮杂环丁烷化合物由式（I）表示。 通过使式（II）的4-乙酰氧基 - 氮杂环丁烷化合物与式（III）的α-卤代丙酸酰胺化合物反应制备β-甲基碳青霉烯类抗生素的中间体是有用的。
-
公开(公告)号：KR1020020024714A
公开(公告)日：2002-04-01
申请号：KR1020000056496
申请日：2000-09-26
Applicant: 한국화학연구원
IPC: A61K9/24
CPC classification number: A61K9/1676 , A61K31/407
Abstract: PURPOSE: Provided is a controlled release pellet containing ketorolac tromethamine, thereby reducing dosage and consequently increasing drug stability and decreasing side effects. CONSTITUTION: The controlled release pellet containing ketorolac tromethamine characteristically consists of a crystalline core(1) having a size of 300-1000 micrometer, an inner layer(2) including ketorolac tromethamine, and a controlled release type of outer layer(3) containing Eudragit as an essential ingredient and optionally a water-soluble polymer.
Abstract translation: 目的：提供含有酮咯酸氨丁三醇的控释丸，从而减少剂量，从而增加药物稳定性和减少副作用。 构成：含有酮咯酸氨丁三醇的控制释放颗粒特征性地由尺寸为300-1000微米的结晶核心（1），包含酮咯酸氨丁三醇的内层（2）和含有Eudragit的控释型外层（3）组成 作为必需成分和任选的水溶性聚合物。
-
-
-
-
-
-
-
-
-
Search Results
22
records
(took 0.023 seconds)
